Being between Scylla and Charybdis is an idiomatic form originating from Greek mythology, which means the obligation of choosing between two evils. Dual antiplatelet therapy after percutaneous coronary intervention is the cornerstone of the treatment for secondary prevention of recurrent ischemic events. Yet, a prolonged or a more potent treatment increases the risk of bleeding, which may be fatal. Clinicians should be aware of the trade-off of both bleeding and ischemia and their potential impact on patients’ health, in order to take the best informed decisions.

, , , , , , ,
F. Zijlstra (Felix) , M. Valgimigli (Marco)
Erasmus University Rotterdam
Department of Cardiology

Costa, F. (2018, April 11). Pharmaco-Mechanical Strategies to Optimize the Balance between Ischemia and Bleeding after Percutaneous Coronary Intervention –Navigating between Scylla and Charybdis–. Retrieved from